Effect ABO Blood Groups and Hormones on Polycystic Ovarian Syndrome
DOI:
https://doi.org/10.59675/V122Keywords:
PCOS, LH, FSH, PLT, HB.Abstract
Background Polycystic ovarian syndrome (PCOS) is an intricate and generally undiagnosed disease. The Maastricht criteria, which include polycystic ovaries, physical or biochemical evidence of hyperandrogenism, and oligo/anovulation, are among the commonly used diagnostic criteria for PCOS. After other potentially aggravating conditions are also checked out, only two of the three will result in a PCOS diagnosis and all related potential consequences, hormone imbalance that occurs during the reproductive years. If you have PCOS, you may not have regular periods. Or perhaps you have long cycles of menstruation. Method: A Karbala obstetrics facility admitted 0 females and 50 persons with polycystic ovarian conditions between February and May 2023. The Rotterdam 2003 criteria were used to diagnose polycystic ovary syndrome. The control group consists of 51 fertile women who underwent ultrasonography examination and had appropriate hormonal levels, resulting in regular menstruation and no excess testosterone symptoms. As a result, it was shown that people under the age of 36 had an increased incidence of this medical condition. The two sets were identical in age, ranging from 26 to 45. Each patient and control were given a survey questionnaire to complete. Our findings revealed that women with blood groups 'O' and 'B' were at the greatest danger of PCOS. Furthermore, our findings show that Rho-negative individuals have no relationship to PCOS Follicle-stimulating hormone (FSH) and luteinizing hormone (lh) levels were determined. The study found that FSH, LH, Prolactin, and TSH increased significantly. Furthermore, the number of CBC tests for WBC, HB, and PLT has significantly increased. Conclusion: While PCOS is more prevalent in B-positive females with blood groups O and B positive, significant differences in hormones (FSH, LH, and PROLACTIN) were found in PCOS patients as well as controls, suggesting a link between PCOS and these modifications
References
Ghai CL. Textbook of practical physiology. 5th ed. New Delhi: Jaypee Brothers; 1999. p. 84-95.
Pal GK. Textbook of Practical Physiology. 3rd ed. Hyderabad: Universities press private limited; 2009. p. 88-94.
Fauser BCJM, Teratais BC, Rebar RW, Legro RS, Balen AH, Lobo R, et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS). Hum Reprod. 2012;27(1):14-24.
Kollmann M, Klaritsch P, Martins WP, Guenther F, Schneider V, Herzog SA, et al. Maternal and neonatal outcomes in pregnant women with PCOS: comparison of different diagnostic definitions. Hum Reprod. 2015;30(10):2396-403.
Sedighi S, Akbari SAA, Afrakhteh M, Esteki T, Majd HA, Mahmoodi Z. Comparison of lifestyle in women with polycystic ovary syndrome and healthy women. Glob J Health Sci. 2015;7(1):228.
Romacho T, Elsen M, Röhrborn D, Eckel J. Adipose tissue and its role in organ crosstalk. Acta Physiol (Oxf). 2014;210(4):733-53.
Laven JS, Imani B, Eijkemans MJ. New approach to polycystic ovary syndrome and other forms of anovulatory infertility. Obstet Gynecol Surv. 2002;57(11):755-67.
Elliott AC, Woodward WA. Statistical Analysis Quick Reference Guidebook SAGA research methods. 2007.
The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2003;19(1):41-7.
Campbell S, Monga A. Gynaecology by Ten Teachers. 17th ed. ELST with Arnold; 2000. p. 58-60.
Khattak ID, Khan TM, Khan P, Alishah SM, Khattak T, Ali A. Frequency of ABO and Rhesus blood groups in district Swat, Pakistan. J Ayub Med Coll Abbottabad. 2008;20(4):127-9.
Yuj G, Kimberg VS, Margenthaler JA. ABO blood type/Rh factor & the incidence & outcomes for patients with triple-negative breast cancer. Ann Surg Oncol. 2012;19(10):3159-64.
George UL, Sengupta A, Karsies D. Polycystic Ovary Syndrome (PCOS) & Other Androgen Excess - Related Conditions: Can Changes in Dietary Intake Make a Difference?. Nutr Clin Pract. 2008;23(1):63-71.
McKenna TJ. Pathogenesis and treatment of polycystic ovary syndrome. N Engl J Med. 1988;318(9):558-62.
Mescher AL. The cytoplasm. In: Junqueira's Basic Histology: Text and Atlas. 14th ed. New York: McGraw Hill; 2016.
McCartney CR, Marshall JC. Polycystic ovary syndrome. N Engl J Med. 2016;375(1):54-64.
Hayes FJ, Taylor AE, Martin KA, Hall JE. Use of a gonadotropin-releasing hormone agonist in the treatment of polycystic ovary syndrome. J Clin Endocrinol Metab. 1998;83(12):2343-9.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Academic International Journal of Veterinary Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
